Business Wire

Bulgaria Joins European Biobanking Research Infrastructure as Full Member

Del

Bulgaria has joined the Biobanking and BioMolecular resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC) at its Assembly of Members, which took place in Bologna on the 23rd May 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604005699/en/

Bulgaria Joins European Biobanking Research Infrastructure as Full Member (Photo: Business Wire)

Bulgaria Joins European Biobanking Research Infrastructure as Full Member (Photo: Business Wire)

Bulgaria will be represented by the Medical University – Sofia and becomes the 21st Member. MUS is the coordinating institution of the National University Complex for Biomedical and Applied Research infrastructure, which has been part of the National Roadmap for RIs since 2014. The Ministry of Education and Science is the financial coordinator of all RIs included in the Roadmap. In the coming months, both the Bulgarian Ministry of Education and Science and MUS will work with BBMRI-ERIC to set up the BBMRI National Node.

Bulgarian Minister of Education and Science Mr Krasimir Valchev said, “I would like first to thank BBMRI-ERIC for the warm welcome of the Bulgarian biobanking and biomedical community to their European family. I am proud that we have excellent research teams who collaborate world-wide and I am convinced we should further strengthen our policies and instruments in support of our bright minds and the research and innovation development in the country. Among our European priorities are acceleration of knowledge transfer and increased access to research results, including via fostering European open science initiatives and ensuring long-term sustainability and openness of pan-European research infrastructures. Bulgaria is committed to continuing its efforts to contribute to the European research area main pillars and common goals.”

BBMRI-ERIC’s Director General Erik Steinfelder said, “It is with great pleasure I welcome Bulgaria to BBMRI-ERIC. Bulgarian biobanks are now connected to the world like never before. At the same time, Bulgarian researchers and biobankers will have access to knowledge, IT tools, and tailor-made guidance by BBMRI-ERIC that will support the further development”.

“This is also a milestone for European research in general”, Steinfelder commented. “While other countries are decreasing investment in research, Bulgaria is showing the way, boosting the development of its biomedical sector”.

Steinfelder concluded saying: “BBMRI-ERIC believes in providing services to Make New Treatments Possible, however, biomedical research does not take place in a vacuum: it requires a multidisciplinary approach. That’s why we are increasing our collaboration with other ERICs to ensure that, in the future, research infrastructures in biomedical research. That is also why we welcome the Council conclusions on accelerating knowledge circulation within the EU: we are going in the same direction”.

BBMRI-ERIC brings together more than 500 biobanks from its Members and one international organisation. The BBMRI-ERIC Directory, the largest sample catalogue in the world, allows users to search more than 100 million samples online. BBMRI’s mission is to facilitate access to biological resources and biomedical facilities and is a central player to when it comes to “Make New Treatments Possible”.

BBMRI is an international organisation established under EU legislation. Its headquarters are in Graz, Austria, and it has a liaison office in Brussels.

BBMRI-ERIC provides support and services to local biobanks via its National Nodes (one per country). The National Nodes are fully involved in the day-to-day management of BBMRI-ERIC and provide feedback from the national level. BBMRI-ERIC services cover three main areas: ethical, legal and societal issues (ELSI), quality management, and IT solutions that allow users to search collections online and request access:

Editor’s Note:

BBMRI-ERIC Members: Austria, Belgium, Bulgaria, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Malta, Latvia, the Netherlands, Norway, Poland, Sweden, United Kingdom

BBMRI-ERIC Observers: Cyprus, Switzerland, Turkey, IARC/WHO

Contact information

BBMRI-ERIC
Luc Deltombe
Communications Manager
Email: luc.deltombe@bbmri-eric.eu
Phone: +43 316 349 917 21
www.bbmri-eric.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third